GU Cancers 2023 | Primary analysis of TROPHY-U-01 Cohort 2

Daniel P. Petrylak, MD, Yale Cancer Center, New Haven, CT, talks on the primary analysis of Cohort 2 of the Phase II TROPHY-U-01 trial (NCT03547973), which investigated sacituzumab govitecan in platinum-ineligible patients with metastatic urothelial carcinoma that have progressed after previous checkpoint inhibitor therapy. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.